文献速递肺外科

切除范围影响伴隐匿性淋巴结病的早期肺癌生存

Extent of Resection Influences Survival in Early-Stage Lung Cancer With Occult Nodal Disease.
PubMed 文献 · Ann Thorac Surg · 2022-02-15

基于美国国家癌症数据库回顾性分析临床IA期非小细胞肺癌(NSCLC)行楔形切除、肺段切除或肺叶切除后检出隐匿性淋巴结病的患者。隐匿性淋巴结病发生率为6.1%。肺段切除与肺叶切除的中位总生存无差异(68.5个月 vs 57.6个月;P=0.200),但楔形切除与更差的总生存独立相关(HR 1.23;95%CI 1.01-1.51;P=0.042)。

要点

  • 临床IA期NSCLC切除后隐匿性淋巴结病发生率为6.1%。
  • 肺段切除与肺叶切除的中位总生存无显著差异(68.5个月 vs 57.6个月;P=0.200)。
  • 楔形切除与更差的总生存独立相关(HR 1.23;95%CI 1.01-1.51;P=0.042)。

核心结论

  • 在经仔细选择的伴隐匿性淋巴结病的临床IA期NSCLC患者中,肺叶切除相比肺段切除未改善总生存。
  • 行楔形切除的患者总生存可能劣于肺叶切除和肺段切除的患者。

研究设计与样本

  • 回顾性分析美国国家癌症数据库(National Cancer Database)中临床IA期NSCLC行楔形切除、肺段切除或肺叶切除且检出隐匿性淋巴结病的患者。
  • 采用多因素Cox回归模型识别与更差生存相关的因素。

主要发现

  • 隐匿性淋巴结病发生于6.1%的行切除的临床IA期患者中。
  • 行楔形切除和肺段切除的患者较肺叶切除患者年龄更大(67.6±9.6岁 vs 66.1±9.3岁 vs 65.6±9.5岁;P=0.004)。
  • 行楔形切除和肺段切除的患者较肺叶切除患者病理分期更晚(pStage III:68.7% vs 50.5% vs 41.5%;P<0.001)。
  • 肺段切除与肺叶切除的中位总生存无差异(68.5个月 vs 57.6个月;P=0.200)。
  • 控制其他术前变量后,楔形切除与更差的总生存独立相关(HR 1.23;95%CI 1.01-1.51;P=0.042)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Minimal literature exists evaluating the impact of the extent of resection on survival in patients with small, early-stage non-small cell lung cancer (NSCLC) found to have occult nodal disease. We hypothesized that sublobar resection has comparable overall survival to patients undergoing lobectomy for clinical stage IA NSCLC that harbors occult nodal disease. METHODS: The National Cancer Database was reviewed for identification of patients with clinical stage IA NSCLC who underwent wedge resection, segmentectomy, or lobectomy and were found to have occult nodal disease. Overall survival was compared between groups, and a multivariate Cox regression model identified factors associated with worse survival. RESULTS: Occult nodal disease occurred in 6.1% of all patients with clinical stage IA disease undergoing resection. Patients undergoing wedge resection and segmentectomy found to have occult nodal disease were older (67.6 ± 9.6 years of age vs 66.1 ± 9.3 years of age vs 65.6 ± 9.5 years of age; P = .004) and had more advanced pathologic stage (pStage III: 68.7% vs 50.5% vs 41.5%; P < .001) than those receiving lobectomy. There was no difference in the median overall survival between segmentectomy and lobectomy (68.5 months vs 57.6 months; P = .200). However, wedge resection was independently associated with worse overall survival when controlling for other preoperative variables (hazard ratio, 1.23; 95% confidence interval, 1.01-1.51; P = .042). CONCLUSIONS: Review of the National Cancer Database suggests that there is no improvement in overall survival in patients undergoing lobectomy vs segmentectomy in carefully selected patients with clinical stage IA NSCLC harboring occult nodal disease. However, those undergoing wedge resection may have worse overall survival than those undergoing both lobectomy and segmentectomy.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Mynard N, Nasar A, Rahouma M, et al. Extent of Resection Influences Survival in Early-Stage Lung Cancer With Occult Nodal Disease. Ann Thorac Surg. 2022. PMID: 35181271. doi:10.1016/j.athoracsur.2022.01.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。